Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Spine J. 2024 Jun;24(6):923-932. doi: 10.1016/j.spinee.2024.01.008. Epub 2024 Jan 21.
Physical therapy (PT) is an important component of low back pain (LBP) management. Despite established guidelines, heterogeneity in medical management remains common.
We sought to understand how copayments impact timing and utilization of PT in newly diagnosed LBP.
STUDY DESIGN/SETTING: The IBM Watson Health MarketScan claims database was used in a longitudinal setting.
Adult patients with LBP.
The primary outcomes-of-interest were timing and overall utilization of PT services. Additional outcomes-of-interest included timing of opioid prescribing.
Actual and inferred copayments based on nonnonprimary care provider visit claims were used to evaluate the relationship between PT copayment and incidence of PT initiation. Multivariable regression models were used to evaluate factors influencing PT usage.
Overall, 2,467,389 patients were included. PT initiation, among those with at ≥1 PT service during the year after LBP diagnosis (30.6%), occurred at a median of 8 days postdiagnosis (IQR 1-55). Among those with at least one PT encounter, incidence of subsequent PT visits was significantly lower for those with high initial PT copayments. High initial PT copayments, while inversely correlated with PT utilization, were directly correlated with subsequent opioid use (0.77 prescriptions/patient [$0 PT copayment] versus 1.07 prescriptions/patient [$50-74 PT copayment]; 1.15 prescriptions/patient [$75+ PT copayment]). Among patients with known opioid and PT copayments, higher PT copayments were correlated with faster opioid use while higher opioid copayments were correlated with faster PT use (Spearman p<.05). For multivariable whole-cohort analyses, incidence of PT initiation among patients with inferred copayments in the 50-75th and 75-100th percentiles was significantly lower than those below the 50th percentile (HR=0.893 [95%CI 0.887-0.899] and HR=0.905 [95%CI 0.899-0.912], respectively).
Higher PT copayments correlated with reduced PT utilization; higher PT copayments and lower opioid copayments were independent contributors to delayed PT initiation and higher opioid use. In patients covered by plans charging high PT copayments, opioid use was significantly higher. Copays may impact long-term adherence to PT.
物理治疗(PT)是腰痛(LBP)管理的重要组成部分。尽管有既定的指南,但医学管理的异质性仍然很常见。
我们旨在了解共付额如何影响新诊断的 LBP 患者的 PT 治疗时机和利用情况。
研究设计/设置:使用 IBM Watson Health MarketScan 索赔数据库进行纵向研究。
腰痛的成年患者。
主要研究结局是 PT 服务的时机和整体利用情况。其他感兴趣的结局指标包括阿片类药物处方的时机。
根据非初级保健提供者就诊索赔推断的实际和推断共付额,用于评估 PT 共付额与 PT 起始发生率之间的关系。多变量回归模型用于评估影响 PT 使用的因素。
总体而言,共纳入 2467389 名患者。在诊断后一年内至少接受一次 PT 服务的患者中(30.6%),PT 治疗的起始时间中位数为诊断后 8 天(IQR 1-55)。在至少有一次 PT 就诊的患者中,高初始 PT 共付额与后续 PT 就诊的发生率显著降低有关。高初始 PT 共付额与 PT 使用呈负相关,但与随后的阿片类药物使用呈正相关(每患者 0.77 张处方[无 PT 共付额]与 1.07 张处方/患者[PT 共付额 50-74 美元];1.15 张处方/患者[PT 共付额 75 美元以上])。在已知阿片类药物和 PT 共付额的患者中,较高的 PT 共付额与更快的阿片类药物使用相关,而较高的阿片类药物共付额与更快的 PT 使用相关(Spearman p<0.05)。对于多变量全队列分析,推断共付额在第 50-75 百分位和第 75-100 百分位的患者中 PT 起始的发生率明显低于第 50 百分位以下的患者(HR=0.893[95%CI 0.887-0.899]和 HR=0.905[95%CI 0.899-0.912])。
较高的 PT 共付额与 PT 使用率降低相关;较高的 PT 共付额和较低的阿片类药物共付额是 PT 起始延迟和阿片类药物使用增加的独立贡献因素。在接受高 PT 共付额计划覆盖的患者中,阿片类药物使用率显著更高。共付额可能会影响长期坚持接受 PT 治疗。